GD
GDSTW
Chi Special Acquisition Corp.Warrants of Chi Special Acquisition Corp. · GDST stock page →
$12.50 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $12.50
1 year
+13.4%
from $11.02 · Oct 27
30 days
0.0%
from $12.50
52-week range
$10.20–12.50
0% from high · low Dec 16
Avg volume 20D
0
Sep 28 spike 0
Short interest
996
0.0%
Days to cover
1.0
at average volume
Price
Daily candles with volume.
No data for this timeframe.
Signal stack
Where each data set points today.
- Short sellersSTEADY
Short interest 0.0% to 996 shares. 1.0 days to cover.
- TrendRANGE
0% above its 50-day average. New closing high $12.50 on Oct 23.
Who's buying
13F| Top holder | Shares | Value |
|---|---|---|
| Hudson Bay Capital Management LP | 409,715 | $17.6K |
| WOLVERINE ASSET MANAGEMENT LLC | 160,544 | $4.8K |
| Walleye Trading LLC | 15,840 | $475.00 |
| UBS Group AG | 6,842 | $103.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jun 17, 2026 Event
GSMS Incorporated, NIACIN EXTENDED-RELEASE TABLETS, USP, 1,000 MG, 90 tablets, Rx only, Manufactured by Kremers Urban Pharmaceuticals Inc., a subsidiary of Lannett, Inc., Seymour, IN 47274, Packaged by GSMS Incorporated, Camarillo, CA 93012. NDC 51407-268-90.
Class II: Failed Dissolution Specifications: During 12-month long-term stability testing, subject lo
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Next Q | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Current Q | — | — | — | $0.00 |
Short side
FINRA· Jun 30, 2026996
shares short
0.0%
vs prior settlement
1.0
days to cover
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Jun 17, 2026
FDA
GSMS Incorporated, NIACIN EXTENDED-RELEASE TABLETS, USP, 1,000 MG, 90 tablets, Rx only, Manufactured by Kremers Urban Pharmaceuticals Inc., a subsidiary of Lannett, Inc., Seymour, IN 47274, Packaged by GSMS Incorporated, Camarillo, CA 93012. NDC 51407-268-90.
Class II: Failed Dissolution Specifications: During 12-month long-term stability testing, subject lot was out of specification (low) for stage 3 disso
May 29, 2026
FDA
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate
WARNING: ABUSE, MISUSE, and ADDICTION Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfa